Short answer
PTC THERAPEUTICS, INC. (PTCT) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Hege Sollie-Zetlmayer appointed Class III director through 2028, filling a board vacancy.
PTC THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Hege Sollie-Zetlmayer appointed Class III director through 2028, filling a board vacancy
- Former PTC chief human resources officer, bringing eight years of company experience and 30 years in biopharma and medical devices
- Annual cash retainer of $50,000 plus meeting-related expense reimbursement
- Initial equity award: 3,475 stock options and 4,000 restricted stock units
- Pro-rated 2026 equity award: 1,738 options and 2,000 restricted stock units
Item 7.01 · Regulation FD Disclosure
- Conference call scheduled for July 30, 2026 at 4:30 p.m. Eastern
- Management to review quarter ended June 30, 2026 financial results
- Call also covers corporate highlights and updates
- Access instructions available in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $360.5M, net income $83.5M versus $64.8M loss, marking a major profitability improvement
- Product revenue $238.8M, up over 100% year over year, led by Sephience revenue $151.3M, up 21% sequentially
- 2026 guidance raised to $1.18B–$1.28B total revenue and $850M–$950M product revenue
- Cash and marketable securities $2.23B, strengthened by $550M 0% convertible notes due 2031
- Pipeline catalysts include votoplam’s 770-patient Phase 3 study, vatiquinone’s approximately 120-patient study, and PTC303’s planned 2027 clinical entry
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PTC THERAPEUTICS, INC. 8-K filings
Get the next PTCT 8-K as it lands
Follow PTCT for push alerts, or ask the research agent what this filing means.